Core Viewpoint - The announcement by Yuan Da Pharmaceutical regarding the acceptance of its new drug application for the innovative radiopharmaceutical conjugate drug TLX591-CDx marks a significant advancement in the field of nuclear medicine for cancer diagnosis, particularly for prostate cancer patients in China [1]. Company Summary - Yuan Da Pharmaceutical has submitted a new drug application (NDA) for TLX591-CDx to the National Medical Products Administration, which has been accepted [1]. - This development is expected to enhance the company's product pipeline in the nuclear medicine sector, specifically targeting tumor diagnosis [1]. Industry Summary - The acceptance of TLX591-CDx signifies the introduction of a globally leading precision diagnostic tool for prostate cancer, which could facilitate early detection, precise classification, and optimization of treatment plans for patients [1].
远大医药创新诊断RDC国内NDA获受理